Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-paclitaxel + gemcitabine followed by mFOLFIRINOX
- Development stage
- Phase 2
- Lead developer
- First Affiliated Hospital, Zhejiang University School of Medicine
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This sequential neoadjuvant chemotherapy regimen consists of an initial phase of nab-paclitaxel plus gemcitabine (the AG regimen) followed by a phase of modified FOLFIRINOX (mFOLFIRINOX). It is being evaluated by the Second Affiliated Hospital, School of Medicine, Zhejiang University in a Phase 3 clinical trial (NCT03750669) for patients with resectable pancreatic ductal adenocarcinoma. The AG regimen involves nab-paclitaxel, a microtubule inhibitor, and gemcitabine, a nucleoside analog. mFOLFIRINOX is a combination of 5-fluorouracil (antimetabolite), leucovorin (folate analogue), irinotecan (topoisomerase I inhibitor), and oxaliplatin (platinum-based antineoplastic). The sequential approach aims to delay drug resistance and improve surgical outcomes compared to upfront surgery by utilizing multiple cytotoxic mechanisms to target cancer cell division and DNA replication.
- Other names
- Sequential AG and mFOLFIRINOXAG regimen followed by mFOLFIRINOXSequential nab-paclitaxel plus gemcitabine and mFOLFIRINOX
02
Targets
DNATOP1 (DNA Topoisomerase I)RNR (Ribonucleotide reductase)TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nab-paclitaxel + gemcitabine followed by mFOLFIRINOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-paclitaxel + gemcitabine followed by mFOLFIRINOX.